CancerVista
CancerVista is an advanced liquid biopsy test designed for multiple solid tumors, enabling non-invasive detection and monitoring through circulating tumor DNA (ctDNA).
Vista ctDNA Test for Solid Tumors
Our CancerVista ctDNA assay is based on a solid tumor–specific gene panel designed to enable precise MRD detection and continuous therapy monitoring through blood-based ctDNA analysis.
High Precision
Detects and monitors mutations of solid tumors with exceptional sensitivity.
Multi-Tumor Coverage
CancerVista detects mutations across multiple solid tumors, including lung, breast, colorectal, and prostate cancers.
Technically Validated
The CancerVista assay has undergone thorough technical validation and is ready for use as an in-house IVD test.
Technical Specifications
CancerVista
Solid Tumors
Technical Validation
Variant Detection: Sensitivity of 93.17% for variants with minor allele frequency (mAF)
≥1%, and specificity >99%.
MRD Detection: Limit of detection (LoD) of 3.30 x 10⁻⁶. Using a detection threshold of
2.5 x 10⁻⁵, we achieved a specificity of 96.7%, sensitivity of 80%, and accuracy of 94.3% for MRD levels
>5.1 x 10⁻⁵.
Clinical Validation
The clinical value of MRD detection is well established in solid tumors, especially colorectal cancer, breast cancer and lung cancer. 1
Application
Indications: The test detects mutations from tumors located at multiple anatomical sites,
including the bladder, brain, breast, cervix, colorectal region, esophagus, head and neck, kidney, liver,
lung, ovary, pancreas, prostate, skin, stomach, thyroid, and uterus.
Gene Spectrum: optimized characteristic mutations of a diverse range of Solid Tumors
Sample Material: 20 ml blood in cfDNA tubes
Time to Result: 2-4 weeks
Clinical Benefits
MRD Detection
Highly sensitive detection of minimal residual disease, often earlier than imaging methods.
Therapy Monitoring
Continuous ctDNA-based monitoring of therapy response.
Early Relapse Detection
Identify relapses months before they appear radiologically.
Risk Stratification
Accurate relapse risk assessment for personalized treatment decisions.
Our tests complement broader liquid biopsy MRD workflows, allowing integration with other molecular and imaging diagnostics.
Test Workflow
Genotyping (Initial Test)
Identification of patient-specific mutations from blood or tissue sample to create an individual mutation profile.
MRD Monitoring
Regular ctDNA testing of known mutations to detect minimal residual disease in follow-up samples.
Report & Interpretation
Detailed report with medical interpretation, available after 2-4 weeks via password-protected email.
References
1 Chen & Zhou. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (2023)
Interested in CancerVista?
Contact us to discuss your study or clinical application, or to request CancerVista testing.